BMS-986235
Modify Date: 2024-01-09 19:33:23
BMS-986235 structure
|
Common Name | BMS-986235 | ||
|---|---|---|---|---|
| CAS Number | 2253947-47-4 | Molecular Weight | 361.34 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C18H17F2N3O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BMS-986235BMS-986235 (LAR-1219) is a selective, orally active formyl peptide receptor 2 (FPR2) agonist, with EC50s of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 has potential for the prevention of heart failure[1]. |
| Name | BMS-986235 |
|---|
| Description | BMS-986235 (LAR-1219) is a selective, orally active formyl peptide receptor 2 (FPR2) agonist, with EC50s of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 has potential for the prevention of heart failure[1]. |
|---|---|
| Related Catalog | |
| In Vitro | BMS-986235 (LAR-1219) inhibits neutrophil chemotaxis and stimulats macrophage phagocytosis, key end points to promote resolution of inflammation[1]. |
| In Vivo | BMS-986235 (LAR-1219) (0.3 mg/kg; p.o.; daily for 24 days) can attenuate left ventricle and global cardiac remodeling after left anterior descending (LAD) in mice[1]. BMS-986235 (1 mg/kg; p.o.) treatment shows the Cmax, T1/2, AUC0-inf, and bioavailability (BA) values of 160 nmol/L, 0.68 hours,120 nmol/L•h, and 24%, respectively[1]. Animal Model: Male C57BL/6 mice[1] Dosage: 0.3 mg/kg Administration: P.o.; daily for 24 days Result: Left ventricle (LV) chamber remodeling is attenuated after myocardial infarction (MI). Reduced infarct length by 39% relative to vehicle. Animal Model: Male mice (BALB/cCrSlc)[1] Dosage: 1 mg/kg Administration: P.o. (Pharmacokinetic Analysis) Result: The Cmax, T1/2, AUC0-inf, and bioavailability (BA) values were 160 nmol/L, 0.68 hours, 120 nmol/L•h, and 24%, respectively. |
| References |
| Molecular Formula | C18H17F2N3O3 |
|---|---|
| Molecular Weight | 361.34 |